XAB2 and colorectal carcinoma: The results demonstrated that USP10 knockdown reduced oxaliplatin resistance in CRC cells, resulting in lower IC50 values and higher apoptotic rates, effects reversed by XAB2 overexpression (Fig. 11E-G).